A5001783218- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Vitamin C and Antioxidants Research
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- Hormonal and reproductive studies
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Bone health and treatments
- Bladder and Urothelial Cancer Treatments
- Colorectal Cancer Treatments and Studies
- Protein Degradation and Inhibitors
- Renal and related cancers
- Multiple Myeloma Research and Treatments
- Economic and Financial Impacts of Cancer
- Ferroptosis and cancer prognosis
- Cancer survivorship and care
- Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
Sidney Kimmel Comprehensive Cancer Center
2016-2025
Johns Hopkins University
2016-2025
Johns Hopkins Medicine
2015-2024
Sidney Kimmel Cancer Center
2014-2024
Duke University
2007-2024
Northwestern University
2018-2024
Hospital Italiano de Buenos Aires
2024
Instituto Universitario Hospital Italiano
2024
Christus Health
2024
University College London
2024
Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target rapamycin kinase, may benefit patients with this disease.In multicenter, phase 3 trial, we randomly assigned 626 previously untreated, poor-prognosis to receive 25 mg intravenous temsirolimus weekly, million U interferon (with an increase 18 U) subcutaneously three times or combination therapy 15 weekly plus 6 weekly. The...
The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection messenger RNA (AR-V7) in circulating tumor cells from men with advanced prostate cancer would be associated resistance to abiraterone.We used quantitative reverse-transcriptase-polymerase-chain-reaction assay evaluate AR-V7 prospectively enrolled patients...
Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since 1940s. We assessed whether concomitant with ADT plus docetaxel would result in longer overall survival than that alone.
Purpose To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer castrate levels of testosterone. Methods A committee investigators experienced conducting defined new consensus criteria by reviewing previous criteria, Response Evaluation Criteria Solid Tumors (RECIST), emerging trial data. Results The Prostate Cancer Clinical Trials Working Group (PCWG2) recommends a two-objective paradigm: (1) controlling, relieving,...
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease anxiety in cancer patients. The effects were studied 51 with life-threatening diagnoses and/or This randomized, double-blind, cross-over trial investigated the a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. high (22 30 administered counterbalanced sequence 5 weeks between sessions 6-month follow-up. Instructions to participants staff...
Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations succeed those from prior Prostate Cancer Clinical Trials Working Groups.An international expert committee of investigators (the Group 3 [PCWG3]) was reconvened expanded met in 2012-2015 formulate updated criteria on basis emerging data validation studies 2 recommendations.PCWG3...
PURPOSE: Prostate-specific antigen (PSA) is a glycoprotein that found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic disease, changes PSA will often antedate bone scan. Furthermore, many but not all investigators have observed an association between decline levels of 50% or greater survival. Since the majority phase II clinical trials for androgen-independent cancer (AIPC) used as marker, we believed it was important to agree on definitions values...
Complete metastatic ablation of oligometastatic prostate cancer may provide an alternative to early initiation androgen deprivation therapy (ADT).To determine if stereotactic ablative radiotherapy (SABR) improves oncologic outcomes in men with cancer.The Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (ORIOLE) phase 2 randomized study accrued participants from 3 US radiation treatment facilities affiliated a university hospital May 2016 March 2018 data...
Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present outcomes CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial more mature follow-up and focus on tumor volume. Patients Methods In this phase III study, 790 cancer were equally randomly assigned receive either ADT combination docetaxel 75...
<h3>Importance</h3> We previously showed that detection of androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer (CRPC) was associated primary resistance to enzalutamide and abiraterone therapy, but the relevance AR-V7 status context chemotherapy is unknown. <h3>Objective</h3> To investigate whether AR-V7–positive patients would retain sensitivity taxane have a differential impact on taxane-treated compared...
Purpose Prostate cancer (PCa) is one of the most common cancers in men. Men with recurrent or metastatic PCa are treated androgen-deprivation therapy (ADT), resulting profound hypogonadism. Because male hypogonadism a risk factor for metabolic syndrome and men have high cardiovascular mortality, we evaluated prevalence undergoing long-term ADT. Patients Methods This was cross-sectional study. We 58 men, including 20 ADT at least 12 months (ADT group), 18 age-matched nonmetastatic who had...
Abstract Optimal reexpression of most genes silenced through promoter methylation requires the sequential application DNA methyltransferase inhibitors followed by histone deacetylase in tumor cell cultures. Patients with myelodysplastic syndrome or acute myeloid leukemia (AML) were treated inhibitor 5-azacitidine (aza-CR) sodium phenylbutyrate. Major responses associated cytogenetic complete response developed patients receiving prolonged dosing schedules aza-CR. Bisulfite sequencing p15...
A randomized, placebo-controlled study based on preclinical and clinical data that supports the potential role of vascular endothelial growth factor in prostate cancer was performed to evaluate addition bevacizumab standard docetaxel prednisone therapy patients with metastatic castration-resistant (mCRPC).
In 2008, an estimated 54,390 Americans were diagnosed with kidney cancer and 13,010 died of the disease in United States. 1 Renal cell carcinoma (RCC) comprises approximately 2% all malignancies, a median age at diagnosis 65 years.The rate RCC has increased per year for past reason this increase is unknown.Approximately 90% renal tumors are RCC, 85% these clear tumors. 2Other, less-common types include papillary, chromophobe, Bellini (collecting) duct tumors.Collecting fewer than 1%...
Purpose We reported previously that the detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells (CTCs) correlated with poor outcomes from use abiraterone and enzalutamide patients castration-resistant prostate cancer (CRPC). Here, we expanded our cohort size to better characterize prognostic significance AR-V7 this setting. Methods prospectively enrolled 202 CRPC starting or investigated value CTC (+ v –) using a CTC-based assay. examined ≥ 50%...
Granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transduced, irradiated tumor vaccines induce potent, T-cell-mediated antitumor immune responses in preclinical models. We report the initial results of a Phase I trial evaluating this strategy for safety and induction patients with metastatic renal cell carcinoma (RCC). Patients were treated randomized, double-blind dose-escalation study equivalent doses autologous, RCC vaccine cells or without ex vivo human GM-CSF gene transfer....
Abstract BACKGROUND Prostate carcinoma (PCa) is one of the most common malignancies in men. Androgen‐deprivation therapy (ADT) used frequently treatment recurrent and metastatic PCa, rendering these men hypogonadal. Because male hypogonadism associated with an unfavorable metabolic profile, PCa have high cardiovascular mortality, authors evaluated effects long‐term ADT on fasting glucose levels, insulin resistance. METHODS To evaluate resistance who received to determine whether alterations...
Purpose To compare the safety and activity of DN-101, a new high-dose oral formulation calcitriol designed for cancer therapy, docetaxel with placebo docetaxel. Patients Methods progressive metastatic androgen-independent prostate adequate organ function received weekly 36 mg/m 2 intravenously 3 weeks 4-week cycle combined either 45 μg DN-101 or taken orally 1 day before The primary end point was prostate-specific antigen (PSA) response within 6 months enrollment, defined as 50% reduction...
Circulating tumor cell (CTC) enumeration has not been prospectively validated in standard first-line docetaxel treatment for metastatic castration-resistant prostate cancer. We assessed the prognostic value of CTCs overall survival (OS) and disease response S0421, a phase III trial plus prednisone with or without atrasentan.CTCs were enumerated at baseline (day 0) before cycle two 21) using CellSearch. Baseline counts changes from day 0 to 21 evaluated association OS, prostate-specific...